B+
Bull case
20%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-01-16 · RankAlpha Sentiment AI
ADPT
Adaptive BiotechnologiesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-01-16 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-01-16 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-01-16
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+24.9
Score
AI commentary
Market commentary around the Jan 13 preliminary release has been cautiously constructive — coverage snippets show analyst averages near $18–21, indicating upside vs the anchor for many desks [#SERP-2]. News flow is focused on MRD commercial traction and upcoming final results, creating a mix of optimism and execution caution [#SERP-1].
RankAlpha Sentiment AI - 2026-01-16
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-02-28eventFinal Q4 & Full Year 2025 Results and Conference CallHigh impact
Company published preliminary results on Jan 13, 2026 and announced it will publish final Q4/FY2025 results and host a conference call; final release + call may materially reprice shares (assumed conference call by 2026-02-28 based on IR notice) [#SERP-1].
2026-04-16catalystAnalyst revisions and updated guidanceHigh impact
Consensus/street targets show a cluster near $18–21; company commentary or results could trigger near-term target revisions and repricing (using a conservative 90-day horizon) [sanity-check: analyst snippets at [#SERP-2], [#SERP-3]].
2027-01-16catalystMRD commercial ramp and reimbursement progressHigh impact
Sustained adoption of MRD assays and favorable reimbursement decisions would drive durable revenue growth and margin expansion; conservative expected date set one year out to reflect multi-quarter commercial build [assumption: +365 days] [#SERP-1].
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-16 • Updated nightlySource: Internal modelMethodology